FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CADILAHC

397.25
-6.45 (-1.6%)
Updated 01:02 05/08 IST

CADILAHC Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for CADILAHC
Disclaimer
0% Bullish
0% Bearish

CADILAHC Buy or Sell - Brokerage Reports

No. of reports in last year
12
No. of analysts
6
Average Consensus Forecast
291.08
Consensus Potential
-40.18%
See CADILAHC Share Price Targets >>

CADILAHC Ratings

Long term CADILAHC rating by FrontPage users
4.3/5 (7 Ratings)
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?

  1. Home
  2. CADILAHC Forum

CADILAHC Share Price Discussion

B
Reputation: -2,230 • Just now

Type
Buy
Instrument
CADILAHC AUG20 FUT
Entry Price
₹398.15
Price@Trade
₹398.5
Target Price
₹408
Stop Price
₹390
Valid Till
Aug 5, 2020 3:20 AM
Margin
₹208,928.5 approx for 2200 Qty
Status
Waiting for entry
Like
Reply
N
Reputation: 4,657 • Just now
Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine from August 6
"ZyCoV-D was found to be safe and well tolerated in the phase I clinical trial. The company will now commence phase II clinical trials from the 6th of August, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,657 • Just now
Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine ZyCoV-D from Aug 6
"The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on July 15, 2020, has been well tolerated," Cadila Healthcare, the listed entity of the group, said in a regulatory filing. Zydus Cadila Chairman Pankaj R Patel said the phase I dosing to establish the safety of ZyCoV-D is an important milestone.
The Economic Times
Like
Reply

CADILA HEALTH TO START PHASE-II TRIALS OF POTENTIAL COVID-19 VACCINE
Like
Reply
P
Reputation: 3,686 • Just now
Pyramidstock in CADILAHC
Cadila btst cmp 400-401 Sl 389 tgt 410-420 resu...
1
Reply
Bharat Biotech, Zydus Cadila complete phase I of Covid-19 vaccine trials
The completion of trials in a short period of time—enrolment and human dosing of the vaccine candidates had started only in mid-July—is likely to be unprecedented
Livemint
1
Reply
R
Reputation: 2,354 • Yesterday 8:55 AM

Type
Buy
Instrument
CADILAHC
Entry Price
₹404.05
Price@Trade
₹404.05
Target Price
₹425
Stop Price
₹385
Valid Till
Aug 11, 2020 3:20 AM
Margin
₹404,050 approx for 1000 Qty
Status
Exited
Exit Price
₹402.8
Net P&L
-₹1,250 (-0.31%)
Like
Reply (1)
Latest replies
Robin @RobinG
Just now

Update
Exited
Exit Price
₹402.8
Net P&L
-₹1,250 (-0.31%)
Pyramidstock in CADILAHC
Cadila btst cmp 400-401 Sl 389 tgt 410-420 resu...
Like
Reply

Cadila btst cmp 400-401 Sl 389 tgt 410-420 result tomorrow #CADILAHC
Like
Reply
N
Reputation: 4,657 • Yesterday 5:36 AM
LIVE Market Technicals with CK Narayan
Strong trends are visible on Cadila chart ahead of the results tomorrow.
The Economic Times
Like
Reply

Type
Buy
Instrument
CADILAHC
Entry Price
₹395.45
Price@Trade
₹395.45
Target Price
₹450
Stop Price
₹350
Valid Till
Aug 11, 2020 3:20 AM
Margin
₹988,625 approx for 2500 Qty
Status
Exited
Exit Price
₹397.45
Net P&L
+₹5,000 (+0.51%)
Like
Reply (1)
Latest replies
Vijay Khandla @vijaykhandla
Yesterday 6:06 AM

Update
Exited
Exit Price
₹397.45
Net P&L
+₹5,000 (+0.51%)

Type
Sell
Instrument
CADILAHC
Entry Price
₹391.6
Price@Trade
₹391.6
Target Price
₹376.7
Stop Price
₹398
Valid Till
Aug 4, 2020 3:20 AM
Margin
₹99,858 approx for 255 Qty
Status
Stoploss Hit
Exit Price
₹398
Net P&L
-₹1,632 (-1.63%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 6:04 AM

Update
Stoploss Hit
Exit Price
₹398

CADILAHC - 1107559
#CADILAHC is bullish today.
can reach the next resistance of 414.
Buy above 402 safe target 410-412
1
Reply
A
Reputation: -47,000 • Aug 3 6:47 AM

Type
Buy
Instrument
CADILAHC
Entry Price
₹393.75
Price@Trade
₹393.6
Target Price
₹500
Stop Price
₹300
Valid Till
Sep 3, 2020 3:20 AM
Margin
₹787.5 approx for 2 Qty
Status
Exited
Exit Price
₹407.35
Net P&L
+₹27.2 (+3.45%)
Like
Reply (3)
Latest replies
Ahmad @gghjjkffgh
Aug 3 6:48 AM

Update
Entry Price Modified
Price @ Update
₹393.75
Original Entry Price
₹393.75
New Entry Price
₹393.75
TrackerBot @trackerbot
Aug 3 6:48 AM

Update
Trade Entered
Entry Price
₹393.75
Ahmad @gghjjkffgh
Just now

Update
Exited
Exit Price
₹407.35
Net P&L
+₹27.2 (+3.45%)
S
Reputation: -46,321 • Aug 3 6:33 AM

Type
Sell
Instrument
CADILAHC
Entry Price
₹394.15
Price@Trade
₹394.15
Target Price
₹378
Stop Price
₹401
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹394.15 approx for 1 Qty
Status
Exited
Exit Price
₹393.5
Net P&L
+₹0.65 (+0.16%)
It's Education Purpose Only. Pleased Don't Follow this Trade Before Self Analysis. It Would Be Harming For You,
Like
Reply (1)
Latest replies
SharePol @sharepol
Aug 3 7:40 AM

Update
Exited
Exit Price
₹393.5
Net P&L
+₹0.65 (+0.16%)
K
Reputation: 30,096 • Aug 3 5:22 AM

Type
Buy
Instrument
CADILAHC AUG20 FUT
Entry Price
₹397.3
Price@Trade
₹397.3
Target Price
₹410
Stop Price
₹388
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹203,578.1 approx for 2200 Qty
Status
Exited
Exit Price
₹395.95
Net P&L
-₹2,970 (-1.46%)
Like
Reply (1)
Latest replies
karun @karun229
Aug 3 7:13 AM

Update
Exited
Exit Price
₹395.95
Net P&L
-₹2,970 (-1.46%)
V
Reputation: -13,768 • Aug 3 4:15 AM

Type
Buy
Instrument
CADILAHC AUG20 410 CE
Entry Price
₹18.65
Price@Trade
₹18.65
Target Price
₹25
Stop Price
₹14
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹82,060 approx for 4400 Qty
Status
Exited
Exit Price
₹16.4
Net P&L
-₹9,900 (-12.06%)
Like
Reply (1)
Latest replies
Vardhan Jp @vardhanjp
Aug 3 6:09 AM

Update
Exited
Exit Price
₹16.4
Net P&L
-₹9,900 (-12.06%)

Type
Sell
Instrument
CADILAHC
Entry Price
₹389.2
Price@Trade
₹389.2
Target Price
₹366.85
Stop Price
₹400.6
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹99,635.2 approx for 256 Qty
Status
Validity Over
Exit Price
₹394.65
Net P&L
-₹1,395.2 (-1.4%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Aug 3 8:50 AM

Update
Validity Over
Exit Price
₹394.65
Net P&L
-₹1,395.2 (-1.4%)
V
Reputation: 5,065 • Aug 3 2:52 AM
vijay jaria in CADILAHC
Govt considering hike in API import duties.. P...
1
Reply
K
Reputation: 2,244 • Aug 3 2:52 AM

Type
Buy
Instrument
CADILAHC AUG20 380 PE
Entry Price
₹17.45
Price@Trade
₹17.45
Target Price
₹25
Stop Price
₹16
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹38,390 approx for 2200 Qty
Status
Exited
Exit Price
₹17.3
Net P&L
-₹330 (-0.86%)
Like
Reply (1)
Latest replies
KETAN @ketan-ByAJmqs3I
Aug 3 2:53 AM

Update
Exited
Exit Price
₹17.3
Net P&L
-₹330 (-0.86%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    8-May-20Prabhudas LilladherSell263
    7-Apr-20Karvy Stock BrokingBuy362
    7-Feb-20Karvy Stock BrokingBuy316
    6-Feb-20Motilal OswalBuy317
    3-Feb-20Nirmal BangBuy314
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 4398405.55390.45403.7
    Aug 3396400.7387.05394.65
    Jul 31367.45396.45367.3388.4
    Jul 30361.5368.5361.3365.65
    Jul 29357.6362.4356360.75
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹367.42
    30 Day Moving Average₹365.54
    50 Day Moving Average₹362.29
    100 Day Moving Average₹333.48
    200 Day Moving Average₹295.04
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    Just now
    Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine from August 6
    Moneycontrol
    NewsBot
    Just now
    Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine ZyCoV-D from Aug 6
    The Economic Times
    NewsBot
    Yesterday 5:36 AM
    LIVE Market Technicals with CK Narayan
    The Economic Times
    NewsBot
    Aug 2 5:38 AM
    US generics business to continue its growth momentum: Cadila Healthcare
    Moneycontrol
    NewsBot
    Aug 2 5:11 AM
    US generics business to continue its growth momentum: Pharma firm Cadila Healthcare
    The Economic Times
    NewsBot
    Jul 31 1:53 AM
    Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
    Moneycontrol
    NewsBot
    Jul 31 1:13 AM
    Hot Stocks | Cadila, ICICI Bank may give up to 16% return in short term
    Moneycontrol
    NewsBot
    Jul 29 3:08 AM
    Dr Reddy's expects to launch Remdesivir in August
    Moneycontrol
    NewsBot
    Jul 25 1:53 AM
    COVID-19: Import licenses for rapid diagnostic kits of 3 firms cancelled, 15 suspended by DCGI
    Moneycontrol
    NewsBot
    Jul 25 2:56 AM
    Much headway in quest for vaccine: Drugmakers might be one step away from the Covid remedy
    The Economic Times
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020